LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Inicio・Lista de Acciones・Odonate Therapeutics Inc

O
Odonate Therapeutics Inc

Cerrado

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

Máximo

Odonate Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 jun 2026, 20:30 UTC

Ganancias

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 jun 2026, 23:58 UTC

Charlas de Mercado

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 jun 2026, 23:46 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 jun 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 jun 2026, 23:41 UTC

Charlas de Mercado

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 jun 2026, 23:01 UTC

Adquisiciones, fusiones, absorciones

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 jun 2026, 23:01 UTC

Adquisiciones, fusiones, absorciones

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 jun 2026, 23:00 UTC

Adquisiciones, fusiones, absorciones

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 jun 2026, 22:57 UTC

Charlas de Mercado

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 jun 2026, 22:50 UTC

Charlas de Mercado

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 jun 2026, 21:07 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 jun 2026, 21:07 UTC

Charlas de Mercado

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 jun 2026, 21:00 UTC

Ganancias

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

2 jun 2026, 20:46 UTC

Ganancias

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 jun 2026, 20:38 UTC

Ganancias

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 jun 2026, 20:21 UTC

Ganancias

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 jun 2026, 20:12 UTC

Ganancias

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks 3Q Product Rev $594M

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks 3Q Loss $177M >PANW

Comparación entre iguales

Cambio de precio

Odonate Therapeutics Inc previsión

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

EBITDA

Beneficio operativo

Acerca de Odonate Therapeutics Inc

Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.